SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31

China SXT Pharmaceuticals, Inc.

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026

$0.11+0.05 (+71.08%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

China SXT Pharmaceuticals, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31
Depreciation & Amortization	0.07	0.08	0.20	0.25	0.32	0.35	0.33	0.18	0.13	–
Stock-Based Compensation	5.31	–	0.35	0.55	2.33	–	–	–	–	–
Deferred Income Taxes	–	–	–	–	0.33	-0.19	-0.10	-0.01	-0.01	–
Change in Accounts Receivable	0.29	-0.26	-0.32	0.91	0.83	-0.52	0.10	-1.81	0.38	-0.94
Change in Inventory	0.04	-0.01	-0.22	0.41	-0.18	0.04	0.04	0.15	-0.27	0.38
Change in Accounts Payable	-0.69	-0.11	-0.03	0.01	-0.02	–	0.30	-0.57	0.97	-1.47
Change in Unearned Revenue	0.04	-0.13	0.03	0.09	-0.19	–	–	–	–	–
Operating Cash Flow	-4.02	-2.35	-1.93	-0.08	0.27	-1.32	0.93	0.24	1.92	0.29
Capital Expenditures	–	0.00	-0.01	–	–	–	-0.13	-0.54	-0.44	-0.18
Sale of Property, Plant & Equipment	–	0.07	–	–	–	–	–	–	–	–
Other Investing Activities	–	–	–	–	0.02	3.13	-3.59	–	–	–
Investing Cash Flow	-1.25	0.06	0.03	-0.01	-0.05	-5.81	-5.50	-0.61	-1.05	-0.19
Stock Issued	–	–	–	–	-0.03	–	–	–	–	–
Debt Repaid	–	–	–	–	–	–	-1.16	0.04	–	–
Financing Cash Flow	14	8.40	-2.62	2.94	1.60	12	3.02	9.04	-0.31	-0.05
Foreign Exchange Rate Adjustments	0.88	-0.07	-0.77	-1.05	0.39	0.78	-0.47	-0.04	0.04	0.00
Net Change in Cash	10	6.05	-5.29	1.80	2.21	6.07	-2.00	8.63	0.59	0.05
Free Cash Flow	–	-2.35	-1.94	–	–	–	0.80	-0.30	1.48	0.11
Income Taxes Paid	–	–	–	0.01	0.02	0.01	0.29	0.00	0.02	0.01
Interest Paid	0.02	0.02	0.02	0.01	0.00	0.00	0.01	0.05	0.02	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 21.9%
Operating margin: -625.9%
Net margin: -545.2%
Return on equity, FY2026: -27.5%

Financial strength

Current ratio: 7.93
Debt to equity: 0.03
Debt to assets: 2.9%
Cash to current liabilities: 647.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –